



Peripheral Artery Disease and Smoking: Epidemiology and Indian Perspectives

Prashant Kumar Mishra, Research Scholar, Malwanchal University, Indore.

Dr Sherin PK, Research Supervisor, Malwanchal University, Indore.

Introduction

Peripheral artery disease (PAD) is a chronic vascular condition characterized by narrowing or blockage of arteries, primarily in the lower extremities, due to atherosclerosis. PAD is a significant public health concern worldwide, contributing to morbidity, reduced quality of life, and increased cardiovascular risk. Among the various modifiable risk factors, smoking stands out as a critical contributor to the development and progression of PAD. The relationship between PAD and smoking is well-established, with smokers being at a markedly higher risk of developing this condition compared to non-smokers.

In India, where tobacco use remains widespread, understanding the epidemiology of PAD in the context of smoking is crucial for designing effective prevention and management strategies. This essay explores the epidemiology of PAD, its relationship with smoking, and its implications in the Indian healthcare landscape, emphasizing the need for targeted interventions and public health initiatives.

Epidemiology of Peripheral Artery Disease

1. Global Burden of PAD

Globally, PAD affects over 200 million individuals, with a rising prevalence due to aging populations, increasing prevalence of diabetes, and other risk factors. PAD is more common in older adults, with prevalence rates ranging from 10% to 25% among individuals aged 55 years and above. It is also a marker of systemic atherosclerosis, indicating a heightened risk of coronary artery disease (CAD) and cerebrovascular events.

The disease burden is disproportionately higher in low- and middle-income countries, including India, where access to healthcare and awareness of PAD are often limited. PAD contributes significantly to healthcare costs due to its chronic nature, associated complications, and the need for long-term management.

2. PAD in India

India faces a growing burden of PAD, influenced by rapid urbanization, lifestyle changes, and the high prevalence of risk factors such as diabetes, hypertension, dyslipidemia, and smoking. Studies estimate the prevalence of PAD in India to range from 4% to 12% in the general population, with higher rates among individuals with diabetes or a history of smoking.



PAD remains underdiagnosed and undertreated in India, partly due to low awareness among both patients and healthcare providers. Symptoms such as intermittent claudication or rest pain are often mistaken for other conditions, leading to delays in diagnosis and treatment.

Smoking as a Risk Factor for PAD

1. Mechanisms Linking Smoking and PAD

Smoking plays a direct and significant role in the pathogenesis of PAD through several mechanisms:

- **Endothelial Dysfunction:** Smoking damages the endothelium, impairing its ability to regulate vascular tone and promote blood flow.
- **Atherosclerosis Acceleration:** Smoking promotes the deposition of lipids in arterial walls, leading to plaque formation and narrowing of arteries.
- **Inflammatory Response:** Smoking triggers chronic inflammation, contributing to plaque instability and progression.
- **Increased Coagulability:** Smoking increases blood viscosity and promotes platelet aggregation, raising the risk of thrombosis.

These mechanisms collectively lead to reduced blood flow to peripheral tissues, manifesting as the hallmark symptoms of PAD.

2. Impact of Smoking on PAD Prevalence and Severity

Smoking is one of the strongest risk factors for PAD, with studies indicating that smokers are up to four times more likely to develop the condition compared to non-smokers. Moreover, the severity of PAD, as measured by reduced ankle-brachial index (ABI) and symptom progression, is significantly greater among smokers. Heavy smoking and longer durations of smoking exposure correlate with higher risks.

Smoking also affects the outcomes of PAD management. Smokers have poorer responses to revascularization procedures, higher rates of limb amputation, and increased mortality compared to non-smokers.

Indian Perspectives on PAD and Smoking

1. Tobacco Use in India

India is one of the largest consumers of tobacco in the world, with diverse forms of tobacco use, including smoking (e.g., cigarettes, bidis) and smokeless tobacco (e.g., gutkha, khaini). According to the Global Adult Tobacco Survey (GATS), nearly 28% of adults in India use tobacco in some form, with smoking being more prevalent among men.

Bidis, a traditional and inexpensive form of smoking, are particularly common in rural and low-income populations. The higher toxicant content of bidis compared to cigarettes exacerbates their harmful effects on vascular health, including PAD risk.



2. Epidemiology of PAD and Smoking in India

While comprehensive national data on PAD prevalence in smokers is limited, regional studies highlight a strong association between tobacco use and PAD. In Indian cohorts, smoking is consistently identified as a major risk factor, alongside diabetes and hypertension.

For instance, studies from urban and rural India report that smokers are significantly more likely to have PAD compared to non-smokers. The prevalence of PAD among bidi smokers, who often begin smoking at a younger age, is particularly alarming due to their prolonged exposure to harmful tobacco products.

3. Challenges in Addressing PAD and Smoking in India

India faces unique challenges in addressing the interplay between PAD and smoking:

- **Low Awareness:** Many individuals remain unaware of the risks associated with smoking and its link to PAD. Symptoms of PAD are often attributed to aging or musculoskeletal issues, delaying diagnosis.
- **Healthcare Access:** Limited access to vascular specialists and diagnostic tools, particularly in rural areas, hampers early detection and management of PAD.
- **Cultural and Economic Factors:** Tobacco use is deeply ingrained in cultural practices, and economic dependence on the tobacco industry poses barriers to stringent anti-smoking policies.
- **High Prevalence of Comorbidities:** The coexistence of diabetes and hypertension in many smokers amplifies their risk of PAD, necessitating integrated management strategies.

Strategies for Prevention and Management

1. Tobacco Control Initiatives

Reducing smoking prevalence is critical to lowering the burden of PAD in India. Tobacco control efforts should include:

- **Public Awareness Campaigns:** Education campaigns highlighting the link between smoking and PAD can motivate individuals to quit smoking and seek medical care.
- **Strengthening Legislation:** Enforcing laws such as the Cigarettes and Other Tobacco Products Act (COTPA) and implementing higher taxes on tobacco products can reduce tobacco consumption.
- **Smoking Cessation Programs:** Accessible cessation programs, including counseling, nicotine replacement therapy (NRT), and pharmacological interventions, can support individuals in quitting smoking.

2. Early Detection and Diagnosis

Improved screening for PAD, particularly among smokers and high-risk populations, is essential. Tools such as ABI measurement and duplex ultrasonography should be made more accessible, even in primary healthcare settings.

3. Integrated Risk Factor Management



Comprehensive management of PAD involves addressing all modifiable risk factors, including smoking, diabetes, hypertension, and dyslipidemia. Smoking cessation is a cornerstone of PAD treatment, significantly reducing the risk of disease progression and complications.

4. Improving Healthcare Access

Expanding the availability of vascular specialists, diagnostic facilities, and rehabilitation programs in rural and underserved areas is critical to improving outcomes for PAD patients.

5. Research and Data Collection

More robust epidemiological studies are needed to quantify the burden of PAD in Indian smokers and evaluate the effectiveness of interventions. Data-driven policies can help prioritize resources and design targeted programs.

Conclusion

Peripheral artery disease is a significant public health challenge in India, with smoking playing a pivotal role in its development and progression. The widespread use of tobacco products, coupled with low awareness and limited healthcare access, exacerbates the burden of PAD in the country. Addressing this issue requires a multifaceted approach, including robust tobacco control measures, early detection initiatives, integrated risk factor management, and improved healthcare infrastructure.

By prioritizing efforts to reduce smoking prevalence and enhance PAD management, India can significantly reduce the morbidity and mortality associated with this debilitating condition. A concerted effort from policymakers, healthcare providers, and the public is essential to tackle the intertwined epidemics of smoking and PAD and improve the vascular health of the nation.

Reference

- 1.Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res.* (2015) 116:1509–26. 10.1161/CIRCRESAHA.116.303849
- 2.Hirsch AT, Haskal ZJ, Hertzler NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic):. *Circulation.* (2006) 113:e463–654. 10.1161/CIRCULATIONAHA.106.174526 [
- 3.Creager MA. Decade in review—peripheral vascular disease: 10 years of breakthroughs in peripheral vascular disease. *Nat Rev Cardiol.* (2014) 11:635–6. 10.1038/nrcardio.2014.153 [DOI] [PubMed] [Google Scholar]
- 4.Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. *Nat Rev Cardiol.* (2017) 14:156–70. 10.1038/nrcardio.2016.179
- 5.Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. *BMJ.* (2018) 360:j5842. 10.1136/bmj.j5842



6. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. *J Vasc Surg.* (2004) 40:1158–65. 10.1016/j.jvs.2004.08.049
7. Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. *Circ Res.* (2021) 128:1818–32. 10.1161/CIRCRESAHA.121.318535 [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Ngu NL, McEvoy M. Environmental tobacco smoke and peripheral arterial disease: a review. *Atherosclerosis.* (2017) 266:113–20. 10.1016/j.atherosclerosis.2017.09.024
9. Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. *JAMA.* (2012) 308:1660–7. 10.1001/jama.2012.13415
10. Conen D, Everett BM, Kurth T, Creager MA, Buring JE, Ridker PM, et al. Smoking, smoking cessation, [corrected] and risk for symptomatic peripheral artery disease in women: a cohort study. *Ann Intern Med.* (2011) 154:719–26. 10.7326/0003-4819-154-11-201106070-00003
11. Young JC, Paul NJ, Karatas TB, Kondrasov SA, McGinagle KL, Crouner JR, et al. Cigarette smoking intensity informs outcomes after open revascularization for peripheral artery disease. *J Vasc Surg.* (2019) 70:1973–83.e5. 10.1016/j.jvs.2019.02.066
12. Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevac WC, Amsterdam EA, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. *J Vasc Surg.* (2014) 60:1565–71. 10.1016/j.jvs.2014.08.064
13. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, et al. Cigarette smoking and progression of atherosclerosis: the atherosclerosis risk in communities (ARIC) study. *JAMA.* (1998) 279:119–24. 10.1001/jama.279.2.119
14. Jones MR, Magid HS, Al-Rifai M, McEvoy JW, Kaufman JD, Hinckley Stukovsky KD, et al. Secondhand smoke exposure and subclinical cardiovascular disease: the multi-ethnic study of atherosclerosis. *J Am Heart Assoc.* (2016) 5:e002965. 10.1161/JAHA.115.002965
15. Mendelson MM, de Ferranti SD. Childhood environmental tobacco smoke exposure: a smoking gun for atherosclerosis in adulthood. *Circulation.* (2015) 131:1231–3. 10.1161/CIRCULATIONAHA.115.015705